Law360, New York (September 28, 2009, 5:11 PM ET) -- Plaintiffs are seeking to obtain class status in a multidistrict litigation accusing Pfizer Inc. and its Warner-Lambert Co. subsidiary of using patent litigation to postpone generic competition for epilepsy treatment Neurontin.
Louisiana Wholesale Drug Co. Inc., Meijer Inc. and Meijer’s distribution unit filed a motion with the U.S. District Court for the District of New Jersey on Friday seeking certification of a class of U.S. individuals and entities that purchased Neurontin directly from Pfizer between July 2000 and September 2009.
The three companies claim that there...
Neurontin Plaintiffs Make Bid For Class Certification
To view the full article, take a free trial now.
